News Center
Details
Renfu Pharmaceutical Makes It onto the Provincial List of Top 100 Private Enterprises.
Release time:
2024-11-15 08:13
Source:
On October 31, the Hubei Provincial Federation of Industry and Commerce and the Wuhan Municipal Federation of Industry and Commerce separately released the 2024 lists of the Top 100 Private Enterprises in Hubei and Wuhan. Renfu Pharmaceutical Group ranked 20th on the list of the Top 100 Private Enterprises in Hubei Province, 11th on the list of the Top 100 Manufacturing Enterprises among private enterprises in Hubei Province, 10th on the list of the Top 100 Private Enterprises in Wuhan, and 2nd on the list of the Top 50 Private Manufacturing Enterprises in Wuhan. The company has also been named to the “Top 100 Private Enterprises in Hubei Province” for 14 consecutive years and has ranked among the top three on the “Top 50 Private Manufacturing Enterprises in Wuhan” for seven consecutive years.
The ranking of the top 100 private enterprises in Hubei and Wuhan is based on the previous year’s operating revenue. In 2023, Renfu Pharmaceutical adhered to its development strategy of “becoming a leader in niche pharmaceutical markets,” continuously promoting R&D innovation, accelerating the cultivation and development of new-quality productivity, actively advancing new industrialization, and consistently implementing the “focus on core businesses” initiative. As a result, the company steadily consolidated and strengthened its competitive edge in its core business areas, maintaining robust growth momentum. Its operating revenue reached 24.525 billion yuan, an increase of 9.79% over the same period last year. As of the third quarter of 2024, the company’s operating revenue totaled 19.143 billion yuan, representing a 5.70% increase compared to the same period last year.
Renfu Pharmaceutical is firmly committed to an innovation-driven development path. Focusing on its core product lines, the company actively leverages its strengths to play a leading role in key areas, continuously boosting its R&D investment. Each year, the company allocates more than 10% of its pharmaceutical industry revenue to R&D. Over the past three years, its R&D investments have totaled RMB 1.054 billion, RMB 1.134 billion, and RMB 1.541 billion, respectively. From 2020 to 2022, the company maintained a steady pace of launching one innovative drug per year. Currently, the company has over 500 products in development, including more than 30 Class 1 new drugs in clinical trials. In terms of patent applications, the company has been granted a total of 826 patents, including 389 invention patents and 82 patents granted overseas, covering regions such as Europe, the United States, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan.
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd